ClinConnect ClinConnect Logo
Search / Trial NCT06327412

The Effects of Aerobic Exercise in Patients With Primary Lower Extremity Lymphedema

Launched by KAYSERI CITY HOSPITAL · Mar 17, 2024

Trial Information

Current as of July 23, 2025

Not yet recruiting

Keywords

Primary Lymphedema Aerobic Execise Cardiopulmonary Exercise Test Cardiopulmonary Rehabilitation

ClinConnect Summary

This clinical trial is looking at how aerobic exercise affects patients with primary lymphedema in their lower legs. Lymphedema is a condition that causes swelling due to a build-up of lymph fluid, and it can impact a person's ability to exercise, their body composition, and their overall quality of life. The study aims to see if adding aerobic exercise to their treatment can help improve these aspects.

To participate in this trial, individuals must be between 18 and 65 years old and have recently completed the first phase of a specific treatment for lymphedema. They should be using special compression garments and be scheduled to continue their treatment. However, some people may not be eligible, including those with certain infections, serious health issues, or conditions affecting their ability to walk. Participants can expect to engage in an exercise program designed for their needs, and their progress will be monitored throughout the study. This research is important as it may help improve treatment options for people living with lymphedema.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients who have completed complete decongestive therapy (CBT) Phase 1 treatment within the last 1 month, use Class 3 compression garments, and are scheduled for CBT Phase 2 treatment.
  • Patients with stage 2-3 unilateral or bilateral primary lymphedema with lower extremity involvement
  • Women and men aged 18-65
  • Patients who agreed to participate in the study and received written voluntary consent form.
  • Exclusion Criteria:
  • Patients who do not agree to participate in the study
  • Patients without cooperation and compliance
  • Presence of phlebo edema, lipedema, cellulitis, lymphocele
  • History of lower extremity venous system disease
  • Presence of acute infection
  • History of malignancy
  • Presence of acute/chronic lung disease (history of acute pulmonary embolism, acute bronchial asthma attack, chronic interstitial lung disease)
  • Chronic liver failure
  • Renal dysfunction
  • Uncontrolled hypertension and diabetes mellitus
  • Presence of orthopedic disease that may prevent walking (joint limitation, ankylosis, amputation)
  • Use of medications known to affect physical performance, heart rate or metabolism (including Beta blockers)
  • Patients who have been included in the CPR (Cardiopulmonary resuscitation) program in the last year

About Kayseri City Hospital

Kayseri City Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor of clinical studies, the hospital combines state-of-the-art facilities with a multidisciplinary team of experienced healthcare professionals. Committed to enhancing therapeutic options and contributing to the scientific community, Kayseri City Hospital focuses on rigorous research protocols and ethical standards to ensure the safety and efficacy of new treatments. Through collaboration with academic institutions and industry partners, the hospital plays a vital role in translating research findings into practical applications that benefit patients and the broader healthcare landscape.

Locations

Kayseri, , Turkey

Patients applied

0 patients applied

Trial Officials

Fatma Gül Ülkü Demir, MD

Study Director

Kayseri City Hospital

Firdevs Akdeniz Çınar

Principal Investigator

Health Sciences University, Kayseri Medical Faculty

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported